Victoria L. Bae-Jump, MD, PhD
Associate Professor
University of North Carolina at Chapel Hill
101 Manning Drive
135 Dauer Drive Campus Box 7435
Chapel Hill,
NC
USA
27514
Biographical Sketch: Dr. Victoria Bae-Jump is an Assistant Professor in the Division of Gynecologic Oncology at the University of North Carolina at Chapel Hill (UNC-CH). She received her MD and PhD degree from Virginia Commonwealth University in Richmond, VA. Following this, she completed her Obstetrics and Gynecology Residency at UNC-CH in 2004 and her Fellowship in Gynecologic Oncology at UNC-CH in 2007. Dr. Bae-Jump is a translational cancer researcher at the UNC-CH Lineberger Comprehensive Cancer Center in the Clinical Research Program. Dr. Bae-Jump’s research focuses on understanding the interactions between cell signaling pathways implicated in ovarian and endometrial cancer pathogenesis as a means to target therapy for this disease, using cell culture, animal models and translational clinical trials. She is also interested in the impact obesity has on ovarian and endometrial cancer development and progression which may invariably dictate different risk reduction strategies and treatment options for this particularly high-risk patient population. In this pursuit, she has investigated many novel targeted therapies for the treatment of endometrial cancer, including mTOR inhibitors, arsenic, a human monoclonal antibody to the insulin growth factor-1 receptor (IGF-1R), soy, genistein, cox-2 inhibitors and most recently, metformin. Her pre-clinical work has led to several investigator-initiated clinical trials, including a pre-operative window study of metformin in obese endometrial cancer patients and a pilot study of meformin for the treatment of endometrial hyperplasia."
Papers:
42
The effects of NT1014, a novel AMPK activator, compared to metformin, on ovarian cancer cell proliferation, apoptosis, and tumor growth
99
Preoperative thrombocytosis and leukocytosis among ovarian cancer patients is associated with postoperative death
144
Relationship between Body Mass Index (BMI) and gene expression profiles of high grade serous ovarian cancers in The Cancer Genome Atlas (TCGA) project
147
The HMG-CoA reductase inhibitor, simvastatin, has anti-tumorigenic effects in ovarian cancer cell lines and a genetically engineered serous ovarian cancer mouse model.
263
Trainee participation in surgery for ovarian cancer: impact on patient outcomes
296
Endometrial cancer survivors may serve as ambassadors for positive health behavioral change
297
The teachable moment: physician counseling and behavioral changes following a diagnosis of endometrial cancer
327
The interaction between glutamine and the mTOR pathway in ovarian cancer cell proliferation and metabolism